Status:
COMPLETED
AZD0837 Extended Release (ER) Japan Study
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
This phase I study will evaluate safety and tolerability after repeated doses of AZD0837.
Eligibility Criteria
Inclusion
- Healthy male Japanese subject aged between 20 to 45 years inclusive
Exclusion
- Acute illness (including ongoing or history of liver disease), trauma or surgical procedures within two weeks before Visit 1 or pre first dose in Visit 2
- Intake of another investigational drug within 4 months before Visit 1 or pre first dose in Visit 2
- Blood donation and/or sampling in excess of 200 mL of whole blood within the preceding 4 weeks, 400 mL of whole blood within the preceding 12 weeks and/or 1200 mL of whole blood within the preceding 12 months, before Visit 1 or pre first dose in Visit 2
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00904800
Start Date
May 1 2009
End Date
June 1 2009
Last Update
July 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Kagoshima, Japan